SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System



	STENT LENGTH (mm)									
Ø (mm)	8	12	16	20	24	28	32	38	48	Overexpansion Capabilites
2.25	H7493941708220	H7493941712220	H7493941716220	H7493941720220	H7493941724220	H7493941728220	H7493941732220	H7493941738220		3.50
2.50	H7493941708250	H7493941712250	H7493941716250	H7493941720250	H7493941724250	H7493941728250	H7493941732250	H7493941738250	H7493941748250	3.50
2.75	H7493941708270	H7493941712270	H7493941716270	H7493941720270	H7493941724270	H7493941728270	H7493941732270	H7493941738270	H7493941748270	3.50
3.00	H7493941708300	H7493941712300	H7493941716300	H7493941720300	H7493941724300	H7493941728300	H7493941732300	H7493941738300	H7493941748300	4.25
3.50	H7493941708350	H7493941712350	H7493941716350	H7493941720350	H7493941724350	H7493941728350	H7493941732350	H7493941738350	H7493941748350	4.25
4.0	H7493941708400	H7493941712400	H7493941716400	H7493941720400	H7493941724400	H7493941728400	H7493941732400	H7493941738400	H7493941748400	5.75
4.5		H7493941712450	H7493941716450	H7493941720450	H7493941724450	H7493941728450	H7493941732450			5.75
5.0		H7493941712500	H7493941716500	H7493941720500	H7493941724500	H7493941728500	H7493941732500			5.75

*Dependent on diameter and length.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
IC-855102-AB.

Boston Scientific
Advancing science for life™

bostonscientific.com.eu

© 2022 Boston Scientific Corporation or its affiliates. All rights reserved.
DINCAR2772EU

Digitally signed by Ostapciuc Alexandr
Date: 2024.11.11 11:55:12 EET
Reason: MoldSign Signature
Location: Moldova
MOLDOVA EUROPEANĂ

Boston Scientific
Advancing science for life™

SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System



Xtra Deliverability
Optimal Healing

Know you'll get there

SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System

Introducing: the next generation SYNERGY™ Bioabsorbable Polymer (BP) Stent. The SYNERGY XD Stent System is equipped with a delivery system designed to make optimal healing even more deliverable.

Innovative Delivery System for **Deliverability beyond compare**

- Increased Pushability*
- Increased Trackability*



Fast Polymer Absorption for **Optimal Healing**

- Proven SYNERGY BP Stent
- Trusted Drug and Abluminal Polymer

* Based on bench testing of SYNERGY and SYNERGY XD BP Stents. Radial Guide Tracking and Radial Push Transmission; 3.00 mm stent systems tested, n=15 units. Bench testing performed by Boston Scientific. Results not necessarily indicative of clinical performance.

Xtra Deliverability

Meaningful innovation of the SYNERGY Delivery System



Increased Trackability
Extended Lubricious Coating*

Increased Pushability
Enhanced Laser-cut Hypotube Technology*

The **SYNERGY XD™ Stent System** combines added **trackability** and **pushability** with a **low-profile** stent platform to enable better navigation of the subclavian artery in radial PCI cases

* Based on bench testing of SYNERGY and SYNERGY XD BP Stents. Radial Guide Tracking and Radial Push Transmission; 3.00 mm stent systems tested, n=15 units. Bench testing performed by Boston Scientific. Results not necessarily indicative of clinical performance.
† Based on the 4.0 - 5.0 mm stent models.

Designed for Flexibility
Short Red Tip and 2-Connector Stent Design

Exceptional Expansion
Up to 5.75mm†

Low Crossing Profile
Thin, Rounded Strut Design

Best-in-Class Visibility
Proprietary PtCr Alloy



Optimal Healing

Fast Absorbing
Bioabsorbable Polymer Advantage

Unlike permanent polymer DES technology, the SYNERGY XD™ Bioabsorbable Polymer is gone shortly after the drug is completely eluted [1]



Optimal Everolimus Drug Delivery
Synchronous drug elution & polymer absorption

Fast Polymer Absorption
The 4-month absorption time is 6x faster than other BP Stent‡

Abluminal Polymer Application
Suppresses neointimal growth while promoting early healing

Thin, Rounded Struts
Stents with thinner struts heal faster than thicker stent struts[2]

‡ Compared to Orsiro BP Stent.
1. Wilson GJ, et al. *Catheter Cardiovasc Interv.*
2. Soucy N, Feygin J et al, *EuroIntervention.* 2010 Nov;6(5):630-7.

Excellent Safety
& Long Term Outcomes

The SYNERGY™ BP Stent has been studied in over 35,000 patients across various patient and lesion complexities

SYNERGY 1 MONTH DAPT LABELLING CE Marked BP Stent

ZERO ST
After patients stopped DAPT at 1-month through 12-months
SENIOR Trial[3]

RANKED #1
Lowest Relative Risk of Def/Prob ST
Kang Network Meta-Analysis[4]

SYNERGY HIGH BLEEDING RISK INDICATION CE Marked BP Stent

0.2% ST
After Patients stopped DAPT at 3-months through 15-months
EVOLVE Short DAPT Trial[§5]

Excellent Results In
COMPLEX PATIENTS
Lowest ST rate in statistically more complex patients
Real-World SCAAR Registry[6]

§ EVOLVE Short DAPT is a prospective, multicenter, single-arm trial defining the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY BP Stent. Approximately 74% of patients enrolled discontinued DAPT at 3-months. N = 1,397 (patients with respective event or sufficient follow-up). Co-primary endpoints: ARC Def/Prob ST and Death/ MI from 3 -15 months.
3. Sarno, G., et al. *Cathet. Cardiovasc. Intervent.*. doi:10.1002/ccd.27030.
4. Kang S, et al. *J Am Coll Cardiol. Intv.*doi:10.1016/j.jcin.2016.03.038.
5. EVOLVE Short DAPT Trial presented by Ajay Kirtane, MD, at TCT 2019.
6. Noad RL, Hanratty CG, Walsh SJ. Initial experience of bioabsorbable polymer everolimus-eluting SYNERGY stents in high-risk patients undergoing complex percutaneous coronary intervention with early discontinuation of dualantiplatelet therapy. *J Invasive Cardiol.* Epub December 2016.